Skip to main content

Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

Publication ,  Conference
Armstrong, AJ; Tombal, B; Sternberg, CN; Higano, CS; Rathkopf, DE; Loriot, Y; Saad, F; Joshua, AM; De Bono, JS; Venner, PM; Carles, J ...
Published in: Journal of Clinical Oncology
May 20, 2014

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

5007 / 5007

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Tombal, B., Sternberg, C. N., Higano, C. S., Rathkopf, D. E., Loriot, Y., … Beer, T. M. (2014). Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). In Journal of Clinical Oncology (Vol. 32, pp. 5007–5007). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5007
Armstrong, Andrew J., Bertrand Tombal, Cora N. Sternberg, Celestia S. Higano, Dana E. Rathkopf, Yohann Loriot, Fred Saad, et al. “Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:5007–5007. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5007.
Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, et al. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5007–5007.
Armstrong, Andrew J., et al. “Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5007–5007. Crossref, doi:10.1200/jco.2014.32.15_suppl.5007.
Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Beer TM. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5007–5007.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

5007 / 5007

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences